Objective: Standard medical treatment for early non-small cell lung cancer (NSCLC) is surgery; however, stereotactic body radiotherapy (SBRT) can be a viable substitute for elderly patients who can no longer tolerate or refuse surgery. The unsurpassed care for elderly patients with early NSCLC remains inconclusive.We conducted a propensity-score matching analysis to compare the efficacy and sideeffects of SBRT and video-assisted thoracic surgery (VATS) in elderly patients with pathologically-proven early NSCLC.
Methods: This single-institution retrospective study included 310 elderly patients who underwent VATS (n = 180) or SBRT (n = 130) from January 2011 to November 2018 at the Tianjin Medical University Cancer Institute and Hospital. Sex, performance status, pathology type, Charlson Comorbidity Index, and T-stage according to the eighth tumor node metastasis classification were considered when performing propensity-score matching.Results: After propensity-score matching, 71 patients were included in each group for analysis. A median follow-up period of 53.5 months was observed for all patients; 72 and 53 months for patients undergoing VATS and SBRT, respectively. Overall survival (p = 0.492), progression-free survival (p = 0.294), locoregional recurrence-free survival (p = 0.866), and distant metastasis-free survival (p = 0.452) did not differ significantly between the VATS and SBRT groups. Multivariate analysis showed a significantThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.